» Articles » PMID: 36974712

Signaling Pathways of the Insulin-like Growth Factor Binding Proteins

Overview
Journal Endocr Rev
Specialty Endocrinology
Date 2023 Mar 28
PMID 36974712
Authors
Affiliations
Soon will be listed here.
Abstract

The 6 high-affinity insulin-like growth factor binding proteins (IGFBPs) are multifunctional proteins that modulate cell signaling through multiple pathways. Their canonical function at the cellular level is to impede access of insulin-like growth factor (IGF)-1 and IGF-2 to their principal receptor IGF1R, but IGFBPs can also inhibit, or sometimes enhance, IGF1R signaling either through their own post-translational modifications, such as phosphorylation or limited proteolysis, or by their interactions with other regulatory proteins. Beyond the regulation of IGF1R activity, IGFBPs have been shown to modulate cell survival, migration, metabolism, and other functions through mechanisms that do not appear to involve the IGF-IGF1R system. This is achieved by interacting directly or functionally with integrins, transforming growth factor β family receptors, and other cell-surface proteins as well as intracellular ligands that are intermediates in a wide range of pathways. Within the nucleus, IGFBPs can regulate the diverse range of functions of class II nuclear hormone receptors and have roles in both cell senescence and DNA damage repair by the nonhomologous end-joining pathway, thus potentially modifying the efficacy of certain cancer therapeutics. They also modulate some immune functions and may have a role in autoimmune conditions such as rheumatoid arthritis. IGFBPs have been proposed as attractive therapeutic targets, but their ubiquity in the circulation and at the cellular level raises many challenges. By understanding the diversity of regulatory pathways with which IGFBPs interact, there may still be therapeutic opportunities based on modulation of IGFBP-dependent signaling.

Citing Articles

Signaling Pathways Driving MSC Osteogenesis: Mechanisms, Regulation, and Translational Applications.

Wang L, Ruan M, Bu Q, Zhao C Int J Mol Sci. 2025; 26(3).

PMID: 39941080 PMC: 11818554. DOI: 10.3390/ijms26031311.


Effects of GDF6 on active protein synthesis by cells of degenerated intervertebral disc.

Tam V, Chopra N, Sima S, Chen P, Sharma R, Chan D Eur Spine J. 2025; .

PMID: 39920317 DOI: 10.1007/s00586-025-08715-1.


Slower Pace of Epigenetic Aging and Lower Inflammatory Indicators in Females Following a Nutrient-Dense, Plant-Rich Diet Than Those in Females Following the Standard American Diet.

Ferreri D, Sutliffe J, Lopez N, Sutliffe C, Smith R, Carreras-Gallo N Curr Dev Nutr. 2024; 8(12):104497.

PMID: 39668946 PMC: 11635705. DOI: 10.1016/j.cdnut.2024.104497.


The signaling landscape of insulin-like growth factor 1.

Khan M, Zugaza J, Torres Aleman I J Biol Chem. 2024; 301(1):108047.

PMID: 39638246 PMC: 11748690. DOI: 10.1016/j.jbc.2024.108047.


[Megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early-stage endometrial adenocarcinoma: a prospective study].

Wang Y, Lai T, Chu D, Bai J, Yan S, Qin H Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(11):2055-2062.

PMID: 39623260 PMC: 11605202. DOI: 10.12122/j.issn.1673-4254.2024.11.01.


References
1.
Steffensen L, Conover C, Bjorklund M, Ledet T, Bentzon J, Oxvig C . Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice. Atherosclerosis. 2016; 248:36-43. DOI: 10.1016/j.atherosclerosis.2016.02.026. View

2.
Xu Y, Kirk N, Venugopal H, Margetts M, Croll T, Sandow J . How IGF-II Binds to the Human Type 1 Insulin-like Growth Factor Receptor. Structure. 2020; 28(7):786-798.e6. PMC: 7343240. DOI: 10.1016/j.str.2020.05.002. View

3.
Seligson D, Yu H, Tze S, Said J, Pantuck A, Cohen P . IGFBP-3 nuclear localization predicts human prostate cancer recurrence. Horm Cancer. 2012; 4(1):12-23. PMC: 3541441. DOI: 10.1007/s12672-012-0124-8. View

4.
Heald A, Cruickshank J, Riste L, Cade J, Anderson S, Greenhalgh A . Close relation of fasting insulin-like growth factor binding protein-1 (IGFBP-1) with glucose tolerance and cardiovascular risk in two populations. Diabetologia. 2001; 44(3):333-9. DOI: 10.1007/s001250051623. View

5.
Marinaro J, Neumann G, Russo V, Leeding K, Bach L . O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. Eur J Biochem. 2000; 267(17):5378-86. DOI: 10.1046/j.1432-1327.2000.01575.x. View